🏆 Honoring the “undisputed coach” of cardiovascular prevention
@ASPCardio gives Roger Blumenthal the Joseph Stokes III Pioneer in Prevention Award
🏆 Congrats to all of this year’s award winners, including Helen Hobbs and Harmony Reynolds
#ASPC2025#CVPrev
For the third year in a row, our master’s program is ranked #1 in the nation by @usnews! 🥇🎉Huge thanks to our students, faculty, staff, alumni & partners. Your dedication helps us to drive the future of nursing. 🔗 Learn more: bit.ly/44egNXS
🫀 New data on #HeartFailure prevention!
#PREVEND study (25 years) shows a 1 in 4 lifetime risk of HF, with modifiable factors playing a key role.
👉🔬 Hypertension is the strongest predictor of HFrEF & HFpEF.
👉💊 Targeted therapies (SGLT2i, GLP-1RA) offer new hope.
👉📉 71% of HFrEF risk in women & 60% in men is modifiable.
Preventing HF is possible! #CardioTwitter#HeartHealth#Prevention
📖 Read more: doi.org/10.1093/eurheartj/eh…
Johns Hopkins University achieves its highest-ever position in the U.S. News & World Report rankings coming in at No. 6 for the nation’s best colleges for undergraduates.
The @usnews report recognizes Johns Hopkins for its excellence in value, innovation, and undergraduate research. hub.jhu.edu/2024/09/24/us-ne…
ALT The image shows the top of a white academic building with a domed roof, rising above a tree with vibrant red leaves. The sky in the background is clear with light clouds, creating a contrast with the fall foliage in the foreground.
We’re proud to announce that @usnews has ranked our BSN program #1, joining our master's programs as the best in the nation. Thank you to our students, faculty, staff, alumni, and partners for their hard work and dedication. Learn more: bit.ly/47ETQwK
Day 1 of the @ISHVnews Cardiovascular Symposium was near and dear to my heart, as it highlighted topics in both #preventivecardiology and #heartfailure . Additionally, it provided the opportunity to catch up with my friend and mentor, @rblument1 🫀🫶🏻
Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC#ACC24
ALT Graphs showing the change from baseline to week 52 in the dual primary end points